Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response

We investigated the pre-clinical activities of two novel histone deacetylase inhibitors (HDACi), ITF-A and ITF-B, in a large panel of pre-clinical lymphoma models. The two compounds showed a dose-dependent anti-proliferative activity in the majority of cell lines. Gene expression profiling (GEP) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mensah, Afua Adjeiwaa, Kwee, Ivo, Gaudio, Eugenio, Rinaldi, Andrea, Ponzoni, Maurilio, Cascione, Luciano, Fossati, Gianluca, Stathis, Anastasios, Zucca, Emanuele, Caprini, Gianluca, Bertoni, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467133/
https://www.ncbi.nlm.nih.gov/pubmed/25671298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467133/
https://www.ncbi.nlm.nih.gov/pubmed/25671298

Ejemplares similares